TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
UCB Pharma AS
Closing information (x1000 EUR)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
20,243
|
21,927
|
25,088 |
Financial expenses |
288
|
172
|
117 |
Earnings before taxes |
528
|
660
|
789 |
Total assets |
13,234
|
11,992
|
13,556 |
Current assets |
13,218
|
11,979
|
13,546 |
Current liabilities |
10,288
|
9,296
|
10,715 |
Equity capital |
2,946
|
2,696
|
2,840 |
- share capital |
44
|
47
|
50 |
Employees (average) | 9 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
22.3%
|
22.5%
|
21.0% |
Turnover per employee | 2,436 | ||
Profit as a percentage of turnover |
2.6%
|
3.0%
|
3.1% |
Return on assets (ROA) |
6.2%
|
6.9%
|
6.7% |
Current ratio |
128.5%
|
128.9%
|
126.4% |
Return on equity (ROE) |
17.9%
|
24.5%
|
27.8% |
Change turnover |
-291
|
-1,844
|
-672 |
Change turnover % |
-1%
|
-8%
|
-3% |
Chg. No. of employees | |||
Chg. No. of employees % |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.